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Abstract
Background: In Pakistan chronic obstructive pulmonary disease (COPD) prevalence is 2.1% in
adults aged >40 years. Despite being a health policy focus, integrated COPD care has remained
neglected, with wide variation in practice.
Aim: To assess whether enhanced care at public health facilities resulted in better control of COPD,
treatment adherence, and smoking cessation.
Design & setting: A two-arm cluster randomised controlled trial was undertaken in 30 public health
facilities (23 primary and 7 secondary), across three districts of Punjab, between October 2014–
December 2016. Both arms had enhanced diagnosis and patient recording processes. Intervention
facilities also had clinical care guides; drugs for COPD; patient education flipcharts; associated staff
training; and mobile phone follow-up.
Method: Facilities were randomised in a 1:1 ratio (sealed envelope independent lottery method),
and 159 intervention and 154 control patients were recruited. The eligibility criteria were as
follows: diagnosed with COPD, aged 18 years, and living in the catchment area. The primary
outcome was change in BODE (Body mass index, airway Obstruction, Dyspnoea, Exercise capacity)
index score from baseline to final follow-up visit. Staff and patients were not blinded.
Results: Six-month primary outcomes were available for 147/159 (92.5%) intervention and 141/154
(91.6%) control participants (all clusters). The primary outcome results cluster-level analysis were as
follows: mean intervention outcome = -1.67 (95% confidence intervals [CI] = -2.18 to -1.16); mean
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control outcome = -0.66 (95% CI = -1.09 to -0.22); and covariate-adjusted mean intervention–
control difference = -0.96 (95% CI = -1.49 to -0.44; P = 0.001).
Conclusion: The findings of this trial and a separate process evaluation study support the scaling of
this integrated COPD care package at primary and secondary level public health facilities in
Pakistan and similar settings.
How this fits in
Integrated COPD care at public facilities is a policy focus and a priority for the Punjab Non-commu-
nicable Disease Control Programme. The two key components of the intervention were medication
and patient education, including smoking cessation. Effectiveness of delivering integrated COPD
care at public health facilities has never been evaluated before in Pakistan. Evidence was required
for the programme to take informed intervention scaling decisions.
Introduction
COPD was found to be the fifth leading cause of death worldwide in 2002, and, if a similar trend
continues, it is expected to become the third leading cause of mortality in 2030.1 According to
World Health Organization, 65 million people suffer from moderate-to-severe COPD, and 90% of
the deaths owing to COPD occur in lower- and middle-income countries.2 According to an epidemi-
ological survey carried out in 11 countries in the Middle East and North African region, the preva-
lence of COPD in Pakistan is 2.1% in adults aged >40 years.3 This prevalence is expected to increase
further given the rising trend in smoking, which is the major risk factor for COPD.4
In Pakistan, public funded health care is delivered at primary level through a network of basic
health units and rural health centres, and at secondary level through sub-district and district-level
hospitals. More than 1000 public healthcare facilities provide free treatment to about 250 000
patients with tuberculosis each year,1 and this indicates the feasibility of delivering integrated care
for priority health conditions.
In 2003, Pakistan developed a National Action Plan for Prevention and Control of Non-Communi-
cable Diseases, which highlighted the importance of strengthening the delivery of integrated non-
communicable disease (NCD) care in the country.5 Despite an emphasis in the plan on the integrated
service delivery for NCDs, including chronic lung conditions, COPD has remained relatively
neglected, and wide variation in diagnosis and treatment practices continues.
Punjab is the country’s biggest province, with a population of 110 million in 36 districts; two-
thirds live in rural areas. The available literature6 and situation review of primary and secondary level
public facilities, which was conducted to inform the intervention design, indicated the following:
missing care protocols and staff training; unavailability of essential material inputs (for example,
inhalers and peak flow meters); and wide variations in diagnosis and treatment practices.
Therefore, a contextualised intervention package was developed for delivering integrated COPD
care at primary and secondary level public healthcare facilities. The intervention package included
contextualised care protocols; doctor and allied staff training (carried out jointly by trainers from the
provincial programme and the Association for Social Development); patient education materials; and
availability of inhalers. The effectiveness of the intervention package at improving the control of
COPD was evaluated using a cluster randomised controlled trial.
Method
The trial is reported here according to the CONSORT guideline recommendations. The trial protocol
has been previously published.1 In the protocol, both COPD and asthma were covered (two diseases
with similar symptoms, such as wheeze). However, after diagnosis, those with asthma were managed
and followed-up as a separate cohort; therefore, asthma outcome will be reported in a separate trial
outcomes article (in preparation). This cluster randomised controlled trial was conducted between
October 2014–December 2016. The trial was carried out in Mandi-Bahauddin, Kasur, and Sargodha
districts (in the Punjab province). These districts have a combined population of approximately 8.75
million.
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In consultation with the three district health offices, all 32 rural health centres and 9 sub-district
hospitals were listed, assessed, and found eligible to participate on the basis of being functional
(that is, having basic clinical and laboratory services in place). From the list of 41 eligible facilities,
the required number of facilities (n = 30) were selected randomly without stratification (resulting in
23 rural health centres and seven sub-district hospitals being selected), and consent for their partici-
pation was obtained from the respective district health offices. Then, with the facilitation of staff at
each selected facility, the communal consent of the catchment population was obtained from the
local community leaders, which included representatives from the women’s council, religious leaders,
businessmen, teachers, press reporters, and health representatives of the union council.
A cluster design was chosen for this study. This is because it would have not been viable to
expect the provider to effectively give or withhold the components of intervention based on
patients’ allocation to treatment, and there could be possible risk of contamination among the
patients. The study only included outpatient departments, which have general doctors who see unre-
ferred primary care patients. Patients were eligible if they were newly diagnosed with COPD and
this was based on the guidelines of the Global Initiative for Chronic Obstructive Lung Diseases,
which are as follows:7 aged 18 years old, and currently residing (and expected to continue residing
for the next 12 months) in the catchment area of the respective health facility. All the patients
attending trial facilities who met the criteria and consented to participate were recruited into the
trial between 18 July 2015–10 March 2016. Excluded patients were those who fulfilled the inclusion
criteria but refused to participate in the trial. Informed consent was obtained from patients using a
standard consent form administered by a ’paramedic’ member of health staff (a qualified technical
staff member with training in general medical care provision) at the respective healthcare facility.
Randomisation and blinding
The selection and randomisation of facilities into intervention and control arms (in a 1:1 ratio) was
done at the central trial unit of the Association for Social Development, and was monitored by the
trial steering committee. The selection of the 30 trial facilities was carried out by listing all 41 eligible
facilities in sealed opaque envelopes before shuffling and randomly selecting 30 of them. Then ran-
domisation of the selected facilities (after obtaining district and communal consent) was done by
again placing their names into sealed opaque envelopes and shuffling them, before a staff member
of the provincial directorate randomly picked 15 envelopes for each treatment arm and opened
them. Owing to the nature of the trial, it was not possible to blind individual patients or healthcare
providers, but the data analyst was blinded to the treatment allocation.
Procedures
The intervention arm facilities were provided with contextualised care protocols and tools, 2-day
training of doctors and allied staff on full set of care tasks, and materials including inhalers and
mobile phones. However, to enable diagnosis and a minimum level of record-keeping, minimal
inputs were provided (for example, 1-day staff training on limited care tasks, and material for diag-
nosis and recording) over and above usual care in control arm facilities. Box 1 gives a summary of
inputs in the two arms.
In both arms, the doctors and allied staff were enabled to screen (on the first visit) and diagnose
patients with COPD. They could also maintain the chronic disease card for each patient (with a line
to record clinical changes per attendance). Additionally, in the intervention arm, the facility staff
were enabled to enhance COPD treatment and follow-up care; for example, they were able to pre-
scribe drugs according to guidelines; educate patients with the help of the pictorial flipchart on pre-
ventive measures, including smoking cessation; dispense free-of-charge inhalers (salbutamol and/or
ipratropium bromide); add or amend drugs as required during the monthly follow-up; and identify
and retrieve patients with delayed monthly follow-up visits, using mobile phone messages or calls.
Further details of lung healthcare experiences are given in the process evaluation study already
published in this journal,8 and the guides and tools are available at http://comdis-hsd.leeds.ac.uk/
resources/ncd-care-package.
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Data collection and outcomes
The patient data at the baseline and subsequent five monthly follow-up visits were recorded on the
chronic disease card as part of the care delivery. The facility doctor recorded the clinical data (that
is, the diagnosis and prescription); ’paramedic’ staff recorded basic data (for example, name, age,
sex, weight, height, peak expiratory flow rate result, and residential address). Patients who did not
turn up for their follow-up visit were declared lost to follow-up if they could not be traced and did
not return for follow-up within 2 months of their last visit due date. The BODE index score,9,10 which
is a composite measure for assessing the severity of disease symptoms, was used to measure the
outcomes in all patients with COPD. A score of 0–2 was chosen as ‘good control’ because this repre-
sents the best 80% 4-year survival, whereas a score of 3–4 is 67%, and 5–6 is 57% (a 1-point change
is a 5%–6% reduction in 4-year survival).11 The spirometry was performed, as an additional research
activity, by an external assessor, who was a qualified public health professional with hands-on train-
ing by a chest specialist at a teaching hospital. The test results were retrieved directly from the data
stored in the spirometer. The primary outcome was the mean change in patient BODE index score
from baseline to 6-month follow-up (calculated as 6-month value minus baseline value). The patients
received points ranging from 0 (lowest value) to 3 (maximal value) for each threshold value of FEV1,
distance walked in 6 minutes, and score on the modified Medical Research Council (mMRC) dys-
pnoea scale.12 For body mass index, the values were 0 or 1. The points for each variable were
added, so that the BODE index score for each patient ranged from 0–10 points. Box 2 gives BODE
index scoring details.
The three secondary outcomes, which were all added post-protocol, were as follows: (a) COPD
control was classed as controlled if a patient’s BODE index score was 0–2, and uncontrolled if it was
3–10 at 6-month follow-up; (b) smoking status as given by patient when asked by an external asses-
sor (smoking or not smoking) at 6 months; and (c) follow-up adherence, which was defined as at 3
of the five required follow-up facility visits made and/or recorded within the 6-month intervention
period.
All data were entered into the SPSS (version 20) database. The quality of data entry was assured
through training of data-entry personnel and checking the quality of data entered at regular
intervals.13
Sample size calculation
At the time of design, the sample size requirement was estimated at a total of 18 clusters and 306
patients with COPD. The sample size was required to detect a mean change of 1 point in the BODE
index score (that is, from the assumed 4 at the baseline), with 80% power, based on a two-tailed
hypothesis test with a 5% significance level. This assumed a standard deviation of 2.0; cluster size of
17; and intracluster correlation coefficient (ICC) of 0.05.
In the initial piloting of the intervention, it was learnt that the assumed rate of patient registration
in each cluster was higher than the actual registration. In light of the piloting, the trial design was
Box 1. Summary of inputs at intervention and control arm facilities
A B C
Inputs Intervention arm facilities Control arm facilities
Contextualised care protocols and
tools
Case management desk guide and counselling tool None
Training of doctors and allied staff
(jointly by the programme staff and
research team)
Full care tasks: screen on the first visit, diagnose, and maintain
patient records; use provided desk guide on how to prescribe,
educate, follow-up, and retrieve patients
Limited care tasks: screen on the first
visit, diagnose, and maintain patient
records only
Material inputs Peak flow meter, recording tools; also salbutamol and ipratropium
inhalers, mobile reminders for patient retrieval
Peak flow meter, and recording tools
only
Access to spirometry at baseline (that is within 2 weeks of registration) and endline (that is completed 6 months after registration) was offered as a research measure-
ment activity (that is not to inform clinical decisions) for all patients in the two trial arms.
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revised and the total number of clusters was increased from 18 to 30 so that the required total num-
ber of patients could be registered, followed, measured, and analysed within the time constraints.
Statistical analysis
To analyse the data, robust methods (suitable for cluster trials with relatively few clusters per arm)
were used.14 For the continuous primary outcome, a crude analysis was initially carried out by calcu-
lating cluster-level outcome values based on the mean of all outcome scores in each cluster. An inde-
pendent t-test was then used to estimate the treatment effect as the mean difference in the cluster-
level outcome values between treatment arms (intervention minus control), with the associated 95%
CI and P value. To adjust for potentially confounding covariates, a two-stage approach was used.
First, a linear regression model was fitted to the individual-level outcome data to adjust for covari-
ates of interest, but excluding the treatment effect. A covariate adjusted difference-residual for each
cluster was then calculated from the model, by calculating the mean difference between the
observed and model predicted outcomes for each cluster. An independent t-test was then used to
estimate the covariate-adjusted treatment effect as the mean difference in the cluster-level differ-
ence-residuals between treatment arms, with the associated 95% CI and P value.
Box 2. BODE index scoring
Clinical
feature
BODE index score points
0 1 2 3
mMRC scale 0–1 2 3 4
6MWD, m 350 250–349 150–249 149
FEV1% pred 65 50–64 36–49 35
BMI, kg/m2 >21 21
mMRC dyspnoea scale ranges from 0–4:
. Score 0–1 indicates breathlessness on exercise only, or on brisk walking
. Score 2 indicates person walks slowly or stops for breath (due to breathlessness)
. Score 3 indicates person stops for breath in less than 100 m walking
. Score 4 indicates person is breathless even while dressing
Distance walked in 6 minutes, contributes 0–3 in the BODE index score. Patient is asked to walk for 6 minutes and his/her score
is calculated as below:
. Score 0 indicates 350 m walking
. Score 1 indicates 250–349 m walking
. Score 2 indicates 150–249 m walking
. Score 3 indicates 149 m walking
The spirometry (FEV1% pred.) contributes 0–3 in the BODE index score:
. Score 0 65 FEV1% pred. (FEV1 is 65% or more of the predicted amount)
. Score 1 50-64 FEV1% pred. (FEV1 is 50–64% of the predicted amount)
. Score 2 36-49 FEV1% pred. (FEV1 is 36–49% of the predicted amount)
. Score 3 35 FEV1% pred. (FEV1 is 35% or less of the predicted amount)
Body mass index (relates height with weight), contributes 0–1 in the BODE index score
. Score 0 indicates BMI >21
. Score 1 indicates BMI 21
Extracted from the doctors’ training module, developed as part of intervention.
6MWD = six-minute walk distance. BODE = Body mass index, airway Obstruction, Dyspnoea, Exercise capacity. BMI = body mass index. mMRC = modified Medical
Research Council.
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The three secondary binary outcomes were analysed similarly. A crude analysis was first done by
calculating cluster level proportions, and an independent t-test was then used to estimate the treat-
ment effect as the risk difference (that is, absolute difference in outcome proportions) between the
intervention and control arms, with the associated 95% CI and P value. To adjust for covariates, the
same two-stage approach was used, but with a logistic regression model used instead to calculate
the cluster-level difference residuals, which were then analysed using an independent t-test as
described above.14
All patients and clusters were analysed according to their original treatment allocations, and com-
plete-case analyses were conducted, excluding any patients from analyses where their outcome and/
or covariate data were missing, depending on the data required in the analysis. Statistical signifi-
cance was set at the 5% level and two-sided P values were calculated. There were no interim analy-
ses planned or conducted. The ICC was estimated from the variance component of a one-way
analysis of variance mode using the R-package ICC.15
Results
A total of 15 health facilities were randomised to each arm in October 2014, and 313 patients were
recruited between 18 July 2015–10 March 2016. All follow-ups were completed by 30 September
2016. The trial flow is shown in Figure 1. The baseline characteristics of individuals in both arms
appeared to be well balanced (Table 1). The patient loss to follow-up rate was modest and similar in
both the arms, with 7.5% in the intervention arm and 8.4% in the control arm.
Between baseline and five monthly follow-up visits, the BODE Index improved (that is, the score
reduced) in both treatment arms, but there was a statistically and clinically significantly greater
reduction in the intervention arm compared with the control arm (adjusted difference -1, 95% CI = -
1.5 to -0.4; P = 0.001). There was also a statistically and clinically significantly greater percentage of
COPD control at 6-month follow-up in the intervention arm compared with the control arm (adjusted
difference 29 percentage points, 95% CI = 12.4 to 45.6; P = 0.001). There was also a statistically and
clinically significantly higher quit rate among smokers at 6-month follow-up in the intervention arm
compared with the control arm (adjusted difference 32 percentage points, 95% CI = 15.4 to 48.5; P
=0.001). Lastly, there was a statistically and clinically significantly greater level of follow-up adher-
ence in the intervention arm compared with the control arm (adjusted difference 40.4 percentage
points, 95% CI = 24.2 to 56.7; P<0.001). Adjusted and crude results were very similar, apart from for
the quit rate among smokers outcome, where the crude result showed a slightly greater quit rate
among smokers (see Table 2).
For all crude analyses, except for the change in smoking, data were available for 147/159 (92.5%)
participants in the intervention arm and for 141/154 (91.6%) participants in the control arm. For the
quit rate among smokers, crude analysis data were available for 56/59 (94.9%) participants in the
intervention arm and 50/54 (92.6%) participants in the control arm. For all the adjusted analyses,
except for quit rate among smokers, data were available for 147/159 (92.5%) participants in the
intervention arm and 141/154 (91.6%) participants in the control arm. For the adjusted analysis of
the change in smoking outcome data were available for 56/59 (94.9%) in the intervention arm and
50/54 (92.6%) in the control arm. Unadjusted primary outcome ICC for: (a) overall = 0.25, (b) the
intervention arm = 0.05, and (c) the control arm = 0.21.
Discussion
Summary
The integrated COPD care package, which included standardised diagnosis, prescription, patient
education, free drugs, and follow-up adherence support, offered in the intervention clusters of pub-
lic health clinics was found to be more effective in terms of achieving the COPD control at 6 months
of completed treatment. In the trial, the better control of COPD in the intervention arm was likely to
be due to a combined effect of the care components; it was not possible to separate the individual
effects of standardised prescription, free-of-cost drug provision, patient education, and follow-up
adherence support.
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Strengths and limitations
The main strength of this study was that it was designed and developed to be potentially replicable
and sustainable in the routine public healthcare system of Pakistan or in similar settings; and the
care and research protocols and tools were piloted before the trial.
The lottery method is known to be a suitable method for randomisation in small populations com-
pared with large populations; therefore, the randomisation was considered adequate for the
study.16 A methodological limitation of the study was that the control arm had to be strengthened
for diagnosis and record-keeping (as in the intervention arm), more than is routine within such public
health facilities, to ensure standardisation for research purposes. However, this is likely to have led
to a reduction in the observed intervention effect compared with what may have been observed if it
had been possible to compare facilities where there had been no interventions at all. This is owing
to the influence of better diagnosis and record-keeping components introduced to the control arm.
Another limitation was that neither the healthcare providers nor the patients were blinded to inter-
vention or control clusters, which increases the likelihood that there was positive bias introduced
into the estimated intervention effect. This is owing to providers and patients being aware of treat-
ment allocation status. The trial also only lasted for a short duration (6 months) relative to the long-
Figure 1. CONSORT trial flow chart
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term nature of COPD, and so a longer study would be necessary to evaluate how sustainable the
improvements in patients’ control of COPD would be.
Comparison with existing literature
As the COPD care intervention included both medication and patient education components, the
reported clinical outcomes (for example, reduction in BODE index score, and adherence to follow-
up) were the combined effect of the two components; that is, medication and patient education.
The researchers were not able to find published results of any intervention trial where similar clinical
outcomes were used to assess the effectiveness of an integrated COPD care at primary and second-
ary level public health facilities.
An intervention trial on COPD care focusing on inhalation technique and adherence to mainte-
nance therapy reported significantly enhanced inhalation score and medication adherence among
patients with COPD.17 Other published studies have also highlighted the importance of prescribing
inhalers at all stages of the disease;7 and educating patients to use inhalers correctly18 to help cope
with the disease.19,20 The BODE index is considered a better measure for classifying the severity of
COPD and predicting the change in health-related quality of life.21 However, a study highlighted the
need for specialist skills to carry out spirometry at primary healthcare level.22 In this trial, specially
trained staff conducting spirometry at the respective health facilities was considered an acceptable
balance of technical requirements and feasibility considerations. The selection and measurement of
Table 1. Baseline characteristics
Characteristics Intervention, n (%) Control, n (%)
Clusters
Total 15 15
Doctors
Male 15 (100.0) 15 (100.0)
Female 0 (0.0) 0 (0.0)
Paramedics
Male 15 (100.0) 15 (100.0)
Female 0 (0.0) 0 (0.0)
Participants
Total 159 (50.8) 154 (49.2)
Mean cluster size, ±SD 10.60 ± 3.85 10.27 ± 3.90
Male 122 (76.7) 111 (72.1)
Female 37 (23.3) 43 (27.9)
Mean age, years, ±SD 48.11 ± 13.89 48.47 ± 12.86
Not educated 104 (70.7) 102 (72.3)
Primary (grade 1–5) 16 (10.9) 15 (10.6)
Secondary (grade 6–12) 24 (16.3) 22 (15.6)
Above secondary (grade >12) 3 (2.0) 2 (1.4)
Mean BMI, kg/m2, ±SD 22.47 ± 4.79 22.45 ± 5.93
Diagnosed with COPD 159 (100.0) 154 (100.0)
Smoker 59 (37.11) 54 (35.06)
Mean BODE index score, ±SDa 3.85 ± 1.94 3.78 ± 1.88
Mean PEFR value, ±SD 232.97 ± 100.88 246.81 ± 108.73
Mean weight, kg, ±SD 58.69 ± 13.18 58.24 ± 14.09
Mean height, inches, ±SD 63.68 ± 3.83 63.63 ± 3.85
aSpirometry was done by an external assessor within 15 days of diagnosis and/or registration.
BODE = Body mass index, airway Obstruction, Dyspnoea, Exercise capacity. BMI = body mass index. COPD = chronic obstructive pulmonary disease. PEFR = peak expira-
tory flow rate. SD = standard deviation.
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effectiveness (using BODE index score) is in accordance with the current knowledge of clinical care
and its outcomes.
Patient non-adherence to the follow-up visits seems to be a major treatment challenge both in
the intervention and control arms (although less so in the intervention compared with the control
arm). A process evaluation of the intervention8 indicated that patients face social challenges to
access care at public facilities (for example, facility timing), and that the provision of free drugs and
use of mobile phone messages can be helpful for patient adherence to the follow-up visits.
The ASSIST trial23 at public health facilities in Pakistan, reported that simplified, tool-assisted
counselling achieved around a 40% smoking quit rate among people with productive cough of 2
week duration (that is, patients with suspected tuberculosis). The evidence-based counselling tool
used in the ASSIST trial was further adapted and included in the care package for chronic obstructive
lung conditions. A relatively higher quit rate (around 54%) achieved through the tool-assisted coun-
selling of COPD patients could either be due to difference in the severity of chest-symptoms
(between patients with COPD and suspected cases of tuberculosis) or the rigour of the quit mea-
surement; for example, only asking the patient (as in the COPD trial) or asking the patient and test-
ing carbon monoxide (as in the ASSIST trial). Both trials in a low-income setting indicate a potentially
high dividend (a 40%–54% quit rate) of counselling smokers with 1 chest symptoms.
Implications for research and practice
The integrated COPD care package for public health facilities has been shown to be effective, lead-
ing to improved COPD control outcomes within the low-income country setting of Pakistan.
In light of the evidence from the trial, and the process evaluation study8 (published separately),
the Department of Health Punjab has decided to do the following: (a) scale-up the COPD care in all
36 districts; and (b) include inhalers in the list of essential drugs and the procurement plans for all
public facilities in the province.
Further research is suggested to explore feasible ways to enhance adherence to follow-up visits,
such as the use of electronic medical records, and to assess the separate effects of the intervention
components, in particular the provision of free drugs.
Table 2. Primary and secondary outcomes
Mean outcome
(95% CI)a
Crude intervention-
control difference
(95% CI);
P valueb
Adjusted intervention-
control difference
(95% CI);
P valueb
Intervention
(clusters = 15)
Control
(clusters = 15)
Primary outcomes
BODE index
score changec
-1.67
(-2.18 to -1.16)
-0.66
(-1.09 to -0.22)
-1.01
(-1.65 to -0.37);
0.003
-0.96
(-1.49 to -0.44);
0.001
COPD controld 66.88%
(54.99 to 78.77)
38.20%
(22.35 to 54.06)
28.68%
(9.68 to 47.67);
0.005
29.03%
(12.41 to 45.64);
0.001
Secondary outcome
Quit rate
among smokerse
53.90%
(34.98 to 72.82)
17.52%
(7.36 to 27.69)
36.38%
(15.66 to 57.10);
0.002
31.98%
(15.42 to 48.54);
0.001
Follow-up
adherencef
65.54%
(52.64 to 78.44)
25.17%
(14.86 to 35.47)
40.38%
(24.57 to 56.18);
<0.001
40.40%
(24.15 to 56.67);
<0.001
aArm-specific mean outcomes and their 95% confidence intervals are calculated from cluster-level mean and/or proportion summary values of outcomes. bAll intervention
minus control differences (that is, intervention effect estimates) are based on crude and/or covariate-adjusted analysis of cluster-level mean and/or proportion summary val-
ues of outcomes. cBODE index score change calculated as outcome at 6-month follow-up minus outcome at baseline. dCOPD control defined as BODE index  2 at 6-
month follow-up. eQuit rate among smokers calculated as smokers who had quit smoking at 6-month follow-up. fFollow-up adherence defined as attending 4 follow-up
visits. All analyses use only complete cases.
BODE = Body mass index, airway Obstruction, Dyspnoea, Exercise capacity. CI = confidence intervals. COPD = chronic obstructive pulmonary disease.
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